In 332 critically ill children and neonates (314 analysed), model-informed precision dosing of vancomycin raised target AUC attainment at 24-48 h versus standard TDM (71.8% v 53.9%); AKI or death was not significantly lower (12.4% v 16.9%).
RCTn = 332
De Cock et al. Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial